Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-chloro-5-hydroxybenzoic acid (3CL-HBA) is a synthetic small molecule that acts as a selective agonist for the hydroxycarboxylic acid receptor 1 (HCAR1), also known as GPR81. HCAR1 is a G-protein coupled receptor primarily known for being activated by L-lactate. In neurobiology research, 3CL-HBA is utilized to investigate the signaling pathways of lactate in the brain, particularly its role in modulating neuronal excitability in regions like the hippocampus and dentate gyrus. Studies presented at the AES Annual Meeting 2025 suggest that HCAR1 activation by 3CL-HBA can enhance baseline excitability and induce activity-dependent rebound responses in dentate granule cells, potentially influencing seizure susceptibility in conditions like temporal lobe epilepsy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-chloro-5-hydroxybenzoic acid.